Start for free
Start for free
Claris Ventures logo

Claris Ventures

Europe, Piemonte, Italy, Torino

Description

Claris Ventures is a venture capital firm focused on early-stage investments in high potential biopharma companies.

Investor Profile

Claris Ventures has made 11 investments, with 0 in the past 12 months and 55% as lead.

Stage Focus

  • Series B (36%)
  • Seed (36%)
  • Series A (27%)

Country Focus

  • Italy (73%)
  • United Kingdom (27%)

Industry Focus

  • Biotechnology
  • Therapeutics
  • Health Care
  • Medical
  • Pharmaceutical
  • Simulation
  • Translation Service
  • Clinical Trials
  • Product Research
  • Biopharma
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Claris Ventures frequently co-invest with?

Italian Angels for Growth
Italian Angels for Growth
Europe, Lombardia, Italy, Milan
Co-Investments: 3
LIFTT
LIFTT
Europe, Piemonte, Italy, Turin
Co-Investments: 2
Sixth Element Capital
Sixth Element Capital
Europe, Buckinghamshire, United Kingdom, Berkhamsted
Co-Investments: 3
SF
Simon Fiduciaria
Europe, Piemonte, Italy, Turin
Co-Investments: 1
3B Future Health Fund
3B Future Health Fund
Europe, Bayern, Germany, Monaco
Co-Investments: 5
Neva SGR
Neva SGR
Europe, Piemonte, Italy, Turin
Co-Investments: 1
Astellas Venture Management
Astellas Venture Management
North America, California, United States, Menlo Park
Co-Investments: 3
2
2invest
Europe, Baden-Wurttemberg, Germany, Heidelberg
Co-Investments: 3
Club degli Investitori
Club degli Investitori
Europe, Piemonte, Italy, Torino
Co-Investments: 4
CDP Venture Capital
CDP Venture Capital
Europe, Lazio, Italy, Rome
Co-Investments: 2

What are some of recent deals done by Claris Ventures?

NeoPhore

Cambridge, Cambridgeshire, United Kingdom

NeoPhore is a provider of novel small molecule therapies intended to treat cancer through stimulation of the immune system.

BiotechnologySimulationTherapeuticsTranslation Service
Series BFeb 1, 2024
Amount Raised: $12,236,423
Resalis Therapeutics

Torino, Piemonte, Italy

Resalis Therapeutics sviluppa un farmaco in grado di inibire un micro-RNA per il trattamento di alcune malattie metaboliche

BiotechnologyClinical TrialsHealth CareMedicalPharmaceuticalProduct ResearchTherapeutics
Series AJan 4, 2024
Amount Raised: $10,947,495
ALKemist Bio

Turin, Piemonte, Italy

ALKemist Bio provides cell treatment to cancer patients.

Therapeutics
SeedDec 21, 2023
Amount Raised: $7,594,377
Repron Therapeutics

Milano, Lombardia, Italy

Repron provides treatments for solid tumour cases where radical excision is not possible and metastasis or recurrence is extremely likely.

BiotechnologyHealth Care
SeedJun 6, 2023
Amount Raised: $2,139,495
Resalis Therapeutics

Torino, Piemonte, Italy

Resalis Therapeutics sviluppa un farmaco in grado di inibire un micro-RNA per il trattamento di alcune malattie metaboliche

BiotechnologyClinical TrialsHealth CareMedicalPharmaceuticalProduct ResearchTherapeutics
SeedFeb 22, 2023
Amount Raised: $10,605,399
NeoPhore

Cambridge, Cambridgeshire, United Kingdom

NeoPhore is a provider of novel small molecule therapies intended to treat cancer through stimulation of the immune system.

BiotechnologySimulationTherapeuticsTranslation Service
Series BJan 19, 2023
Amount Raised: $7,435,460
Sibylla Biotech

Trento, Trentino-Alto Adige, Italy

Sibylla Biotech developed small molecule folding interfering degraders (FIDs) that can address a range of therapeutic areas.

BiotechnologyHealth CareMedicalPharmaceutical
Series AOct 4, 2022
Amount Raised: $22,962,731
Kither Biotech

Torino, Piemonte, Italy

Kither Biotech is a pharmaceutical product company that developmens of new drugs to treat chronic inflammatory diseases

BiopharmaBiotechnologyLife Science
Series BMar 16, 2022
Amount Raised: $20,390,124
Resalis Therapeutics

Torino, Piemonte, Italy

Resalis Therapeutics sviluppa un farmaco in grado di inibire un micro-RNA per il trattamento di alcune malattie metaboliche

BiotechnologyClinical TrialsHealth CareMedicalPharmaceuticalProduct ResearchTherapeutics
SeedAug 5, 2021
Amount Raised: $7,099,499
NeoPhore

Cambridge, Cambridgeshire, United Kingdom

NeoPhore is a provider of novel small molecule therapies intended to treat cancer through stimulation of the immune system.

BiotechnologySimulationTherapeuticsTranslation Service
Series BMar 9, 2021
Amount Raised: $21,108,883
c-shape-1
c-shape-2

Ready to Raise Capital?

Founders in our network have raised from Y Combinator, Sequoia, a16z, and more. You could be next.

Find investors

Pages

Find investorsPricing

Free tools

Pre-Money and Post-Money Valuation Calculator